Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Phase I study of taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer.

Phase I study of taxol and granulocyte colony-stimulating factor in patients with refractory... To increase the taxol dose beyond the current standard dose intensity of 175 mg/m2 per 21 days in patients with refractory ovarian cancer. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of clinical oncology : official journal of the American Society of Clinical Oncology Pubmed

Phase I study of taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer.

Sarosy, G; Kohn, E; Stone, D A; Rothenberg, M; Jacob, J; Adamo, D O; Ognibene, F P; Cunnion, R E; Reed, E
Journal of clinical oncology : official journal of the American Society of Clinical Oncology , Volume 10 (7): -1094 – Jul 23, 1992
Download PDF

Phase I study of taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer.


Abstract

To increase the taxol dose beyond the current standard dose intensity of 175 mg/m2 per 21 days in patients with refractory ovarian cancer.

Loading next page...
 
/lp/pubmed/phase-i-study-of-taxol-and-granulocyte-colony-stimulating-factor-in-m0VmfJujo2

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN
0732-183X
DOI
10.1200/JCO.1992.10.7.1165
pmid
1376773

Abstract

To increase the taxol dose beyond the current standard dose intensity of 175 mg/m2 per 21 days in patients with refractory ovarian cancer.

Journal

Journal of clinical oncology : official journal of the American Society of Clinical Oncology – Pubmed

Published: Jul 23, 1992

There are no references for this article.